Literature DB >> 1204278

Clinical pharmacology of nabilone, a cannabinol derivative.

L Lemberger, H Rowe.   

Abstract

Nabilone is a modified cannabinol derivative with central nervous system activity. Administration of nabilone in single doses of 1 to 5 mg results in dose-related pharmacologic effects in man. One and 2.5 mg doses of nabilone induced relaxant and sedative effects in all subjects. No euphoria, dry mouth, tachycardia, or postural hypotension was seen after 1 mg, minimal effects were seen after 2.5 mg, and marked effects were seen after 5 mg. Effects were evident within 60 to 90 min and persisted for 8 to 12 hr. Nabilone produced no significant tachycardia. There were no changes in supine blood pressure; however, marked postural hypotension occurred after the 5-mg dose. The administration of nabilone at doses of 1 mg or 2 mg two times daily resulted in euphoria and dry mouth during the first two days of drug; thereafter tolerance developed to these effects but there was no apparent decrease in relaxation. Subjects challenged with a single 5-mg dose of nabilone showed a 66% reduction in symptoms and signs after the 7-day drug period compared to that of the same dose after 1 wk of placebo. Comparison of nabilone with other cannabinol derivatives suggests that some of the undesirable pharmacologic effects can be separated within the group.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1204278     DOI: 10.1002/cpt1975186720

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

Review 1.  Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.

Authors:  Celina S Liu; Sarah A Chau; Myuri Ruthirakuhan; Krista L Lanctôt; Nathan Herrmann
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

2.  Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.

Authors:  Gillinder Bedi; Ziva D Cooper; Margaret Haney
Journal:  Addict Biol       Date:  2012-01-19       Impact factor: 4.280

Review 3.  Toward drugs derived from cannabis.

Authors:  R Mechoulam; E A Carlini
Journal:  Naturwissenschaften       Date:  1978-04

4.  A single dose study of nabilone, a synthetic cannabinoid.

Authors:  R M Glass; E H Uhlenhuth; F W Hartel; C R Schuster; M W Fischman
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

5.  Cannabis and the cardiovascular system.

Authors: 
Journal:  Br Med J       Date:  1978-02-25

6.  Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy.

Authors:  N Niederle; J Schütte; C G Schmidt
Journal:  Klin Wochenschr       Date:  1986-04-15

Review 7.  Nabilone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  A Ward; B Holmes
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

8.  Reinforcing properties of oral delta 9-tetrahydrocannabinol, smoked marijuana, and nabilone: influence of previous marijuana use.

Authors:  J H Mendelson; N K Mello
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 9.  Cannabinoids for neuropathic pain.

Authors:  Perry G Fine; Mark J Rosenfeld
Journal:  Curr Pain Headache Rep       Date:  2014-10

10.  Review of cannabinoids and their antiemetic effectiveness.

Authors:  B J Vincent; D J McQuiston; L H Einhorn; C M Nagy; M J Brames
Journal:  Drugs       Date:  1983-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.